Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin + Nivolumab + Chemotherapy in ARID1A Mutated Advanced Gastrooesophageal Carcinoma (ARES)
NCT07213557Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of simvastatin in gastroesophageal junction carcinoma (GEJ), sponsored by National Cancer Institute. Started Mar 2026; status: recruiting.
02
Drugs
simvastatin
03
Conditions
gastroesophageal junction carcinoma (GEJ)
Beyond the preview
Go deeper on NCT07213557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213557.